Welcome to our dedicated page for Odyssey Health news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Health stock.
Odyssey Health Inc. (ODYY) drives innovation in life-enhancing medical solutions through strategic asset development and clinical advancements. This page serves as the definitive source for verified news and official updates from the company, offering stakeholders timely insights into its progress.
Investors and industry professionals will find curated press releases covering product developments, research milestones, and strategic partnerships. Our repository includes updates on regulatory progress, financial disclosures, and technology acquisitions – all essential for understanding ODYY's position in the medical device sector.
Key focus areas include neurological health innovations, FDA clearance updates, and partnership announcements with healthcare organizations. The collection emphasizes clinically validated advancements while maintaining neutral reporting on corporate developments.
Bookmark this page for direct access to Odyssey Health's latest communications. Check regularly for updates that could impact market positioning and investment considerations in the evolving medical technology landscape.
Odyssey Health (OTCQB: ODYY) announced a multi-million-dollar, nine-year maintenance service contract for a commercial medical property, which the company says will create a stable, recurring revenue stream and support its transition to cash-generating operations.
The company also secured a financing facility of up to $25 million; an initial tranche of $500,000 will be used to advance Odyssey’s BreastCheck® sub-licensing program for a rapid, non-invasive breast screening test. Management described the deals as improving financial flexibility and enabling strategic commercialization initiatives.
Odyssey Health (OTCQB: ODYY) announced on October 16, 2025 that its subsidiary Odyssey Medical Devices signed a sub-licensing agreement for exclusive worldwide marketing and distribution rights to BreastCheck®, a non-invasive, at-home breast screening test with 15-minute results. The agreement is subject to closing conditions.
BreastCheck® is described as a first-line screening tool (not a mammogram replacement) and the technology is FDA registered in the United States and registered with relevant authorities in the European Union and the United Kingdom. Management expects near-term commercialization and initial revenue, signalling a move from development-stage to revenue-generating medtech.
Odyssey Health (OTCQB: ODYY) has announced plans to advance the development of its patented Save A Life (SAL) choking rescue device, targeting an FDA submission in 2026. The device is designed as a vacuum-based solution for removing lodged objects from a choking victim's throat.
The SAL device features a vacuum chamber with a replaceable mouthpiece that can be quickly deployed in emergencies. When activated, it creates an appropriate vacuum force to dislodge throat obstructions without causing trauma to the victim. The company highlights the significant market need, citing 5,000 annual choking deaths in the US and over 100,000 yearly emergency room visits related to choking incidents.
FAQ
What is the current stock price of Odyssey Health (ODYY)?
What is the market cap of Odyssey Health (ODYY)?
